Citizens First (CZFC) At $26.55 Forms Top; Impax Laboratories (IPXL)’s Sentiment Is 1.14

June 18, 2018 - By Martha Paddon

Citizens First Corporation (NASDAQ:CZFC) Logo

Citizens First Corporation (CZFC) formed multiple top with $27.35 target or 3.00% above today’s $26.55 share price. Citizens First Corporation (CZFC) has $67.37M valuation. The stock increased 2.12% or $0.55 during the last trading session, reaching $26.55. About 851 shares traded. Citizens First Corporation (NASDAQ:CZFC) has risen 30.23% since June 18, 2017 and is uptrending. It has outperformed by 17.66% the S&P500. Some Historical CZFC News: ; 19/04/2018 – Citizens First 1Q EPS 43c; 19/04/2018 – CITIZENS FIRST CORP CZFC.O SETS QUARTERLY CASH DIVIDEND OF $0.07/SHR; 12/03/2018 Penn Governor: Governor Wolf Introduces “Citizens First” Ethics Reform Plan; 20/04/2018 – DJ Citizens First Corporation, Inst Holders, 1Q 2018 (CZFC)

Impax Laboratories Inc (IPXL) investors sentiment decreased to 1.14 in Q1 2018. It’s down -0.12, from 1.26 in 2017Q4. The ratio worsened, as 79 investment professionals increased and opened new equity positions, while 69 sold and decreased stakes in Impax Laboratories Inc. The investment professionals in our database now own: 71.42 million shares, down from 73.13 million shares in 2017Q4. Also, the number of investment professionals holding Impax Laboratories Inc in top ten equity positions was flat from 1 to 1 for the same number . Sold All: 21 Reduced: 48 Increased: 54 New Position: 25.

Investors sentiment increased to 1.5 in Q1 2018. Its up 0.67, from 0.83 in 2017Q4. It improved, as 0 investors sold Citizens First Corporation shares while 4 reduced holdings. 0 funds opened positions while 6 raised stakes. 441,129 shares or 0.25% less from 442,227 shares in 2017Q4 were reported. Acadian Asset Mgmt Llc reported 0% of its portfolio in Citizens First Corporation (NASDAQ:CZFC). Alliancebernstein Lp holds 77,750 shares. Blackrock accumulated 695 shares or 0% of the stock. Us Bankshares De holds 28,275 shares. Salzhauer Michael invested in 20,000 shares. 100 were reported by Deutsche Fincl Bank Ag. Gendell Jeffrey L reported 103,978 shares or 0.3% of all its holdings. Wells Fargo Mn owns 0% invested in Citizens First Corporation (NASDAQ:CZFC) for 772 shares. Morgan Stanley has 0% invested in Citizens First Corporation (NASDAQ:CZFC) for 376 shares. Hl Fincl Lc owns 73,765 shares. Royal State Bank Of Canada invested in 0% or 1 shares. Vanguard Incorporated, Pennsylvania-based fund reported 25,201 shares. Geode Capital Mngmt Limited Liability holds 0% or 14,760 shares in its portfolio. Cutler Management Ltd Liability Corporation holds 59,210 shares. 21,516 were accumulated by Dimensional Fund Advsr Ltd Partnership.

Since January 25, 2018, it had 6 insider buys, and 1 sale for $87,621 activity. Iverson Mark also bought $18,061 worth of Citizens First Corporation (NASDAQ:CZFC) on Tuesday, February 6. 206 Citizens First Corporation (NASDAQ:CZFC) shares with value of $4,919 were bought by GRISE SARAH GLENN. Milliken Amy Hale bought $11,543 worth of stock. Perkins Jeff bought $66,713 worth of stock or 2,725 shares. Furlong Kent E. bought 1,000 shares worth $24,250. Another trade for 2,500 shares valued at $61,615 was made by LIVELY MARC R. on Monday, March 26.

Ratings analysis reveals 0 of Impax Labs’s analysts are positive. Out of 5 Wall Street analysts rating Impax Labs, 0 give it “Buy”, 1 “Sell” rating, while 4 recommend “Hold”. The lowest target is $15.0 while the high is $18.0. The stock’s average target of $17 is -7.10% below today’s ($18.3) share price. IPXL was included in 5 notes of analysts from September 27, 2016. The company was initiated on Wednesday, December 28 by Janney Capital. RBC Capital Markets maintained the shares of IPXL in report on Thursday, November 10 with “Sector Perform” rating. The rating was downgraded by WallachBeth Capital to “Hold” on Monday, November 14. The firm earned “Neutral” rating on Tuesday, September 27 by Goldman Sachs. The stock has “Underperform” rating by Bank of America on Monday, November 7.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products. The company has market cap of $1.31 billion. It operates in two divisions, Impax Generics and Impax Specialty Pharma. It currently has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

It closed at $18.3 lastly. It is up 0.00% since June 18, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical IPXL News: ; 20/04/2018 – DJ Impax Laboratories Inc, Inst Holders, 1Q 2018 (IPXL); 27/04/2018 – Amneal And Impax Receive FTC Clearance For Business Combination; 07/05/2018 – CORRECT: IMPAX LABS 1Q REV. $142.4M; 20/04/2018 – FDA: Abbreviated New Drug Application (ANDA): 202552 Company: IMPAX LABS INC; 07/05/2018 – IMPAX LABS 1Q REV. $142.4M, EST. $181.6M; 07/05/2018 – Correct: Impax Laboratories 1Q Loss $130.9M; 27/04/2018 – U.S. FTC SAYS IT REQUIRES GENERIC DRUG MARKETERS AMNEAL PHARMACEUTICALS LLC AND IMPAX LABORATORIES INC. TO DIVEST RIGHTS TO 10 GENERIC MEDICATIONS AS CONDITION OF MERGER; 16/04/2018 – Impax Labs Closes Above 200-Day Moving Average: Technicals; 27/03/2018 – Impax Hldrs Approve Proposed Business Combination With Amneal; 27/03/2018 – Impax Laboratories: Deal Expected to Close in 2Q

Citizens First Corporation (NASDAQ:CZFC) Institutional Positions Chart